A retrospective cohort study found that switching from dual therapy to monotherapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) did not result in different outcomes for patients. The study, conducted at Ohio State University Wexner Medical Center, included 140 patients with MRSA who received dual therapy with ceftaroline and daptomycin, and were then either maintained on dual therapy or switched to monotherapy. There were no significant differences in 60-day clinical outcomes, including rates of recurrence, readmission, or infection-related mortality. This was also true for patients with specific conditions such as endocarditis, epidural abscess, or osteomyelitis. The study was limited by its small sample size and retrospective design.
Source link
Monotherapy as Effective as Dual Therapy for Methicillin-Resistant Staphylococcus aureus
